Welcome to MyStrategist, the digital home for MedTech Strategist.

MedTech Strategist, the global medical device industry's most trusted resource, will help you stay ahead of the opportunities and obstacles that are impacting your corporate strategy. We invite you to explore our coverage. Think Strategically. Subscribe Today

Browse   Latest Issue
Latest from MedTech Strategist

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.


Start-Ups

Opharmic Enables Needle-Free Ocular Drug Delivery

Macromolecules like anti-VEFG are not deliverable as eye drops because they can’t normally penetrate the surface of the eye. But with a novel application of low-frequency ultrasound, Opharmic’s MeticTouch can push drugs to the back-of-the eye, so patients don’t have to undergo the needle.

Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways

Start Trial
Latest from MedTech Strategist

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.


Start-Ups

Next-Gen Avisi Technologies Aims for “One and Done” in a MIGS Device

Avisi’s MIGS device, VisiPlate, has been designed to lower intraocular pressure in patients with moderate to severe glaucoma, a 2.6 million patient market in the US worth billions of dollars. The company believes it doesn’t make tradeoffs between safety and efficacy; it believes it has created an implant that will achieve a durable and effective treatment, once and for all.

Don't Just Advertise... Strategize!

Advertise with MedTech Strategist and be seen by medtech's most influential executives.

Learn More
Latest from MedTech Strategist

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.


Start-Ups

Next-Gen Avisi Technologies Aims for “One and Done” in a MIGS Device

Avisi’s MIGS device, VisiPlate, has been designed to lower intraocular pressure in patients with moderate to severe glaucoma, a 2.6 million patient market in the US worth billions of dollars. The company believes it doesn’t make tradeoffs between safety and efficacy; it believes it has created an implant that will achieve a durable and effective treatment, once and for all.

Discover the opportunities and challenges that impact the global medtech regulatory and reimbursement community with Market Pathways.

Subscribe   Free Premier Issue   Learn More